FDA gives orphan-drug designation to Apogenix's MDS drug Apocept

02/8/2013 | Pharmaceutical Business Review Online

The FDA granted orphan-drug status to Apocept, or APG101, Apogenix's investigational drug for myelodysplastic syndromes. The company said it launched an early-stage trial in Germany to assess Apocept's safety, efficacy and tolerability in MDS patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC